Today: 23 December 2025
Subscribe
Browse Category

Biotechnology News 6 November 2025 - 17 November 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

As of this afternoon, Galmed Pharmaceuticals shares were changing hands around $1.18, up roughly 13% on the day, with more than 41 million shares traded—massively above the stock’s usual daily volume. TipRanks What Galmed Announced Today From its headquarters in
17 November 2025
 ·  ·  ·  ·  · 
Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update

Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update

All of today’s Autonomix (AMIX) news in one glance – 17 November 2025 As of this afternoon on November 17, 2025, all company‑specific news about Autonomix Medical, Inc. (NASDAQ: AMIX) centers on the same core development: new quality‑of‑life data from
17 November 2025
 ·  ·  ·  ·  · 
Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

What Zymeworks Announced Today Before the U.S. market open on November 17, 2025, Vancouver‑based Zymeworks Inc. (ZYME) released topline Phase 3 data from its pivotal HERIZON‑GEA‑01 study, evaluating Ziihera (zanidatamab‑hrii) in first‑line treatment of HER2‑positive locally advanced or metastatic gastroesophageal
17 November 2025
 ·  ·  ·  ·  ·  ·  · 
Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Vancouver / Jerusalem – November 13, 2025 – Shares of Clearmind Medicine Inc. (NASDAQ: CMND), a clinical‑stage psychedelic and neuroplastogen biotech company, jumped sharply on Thursday after the firm announced final approval to expand its FDA‑regulated Phase 1/2a clinical trial
13 November 2025
 ·  ·  ·  ·  · 
Humacyte (HUMA) Q3 2025: Symvess Sales Surge; IND Filed for CABG as Dialysis Data Advance — Nov 12, 2025

Humacyte (HUMA) Q3 2025: Symvess Sales Surge; IND Filed for CABG as Dialysis Data Advance — Nov 12, 2025

Durham, N.C. — November 12, 2025 — Humacyte, Inc. (NASDAQ: HUMA) reported third‑quarter results and a pipeline update this morning, highlighting accelerating Symvess™ sales, new clinical data in dialysis access, and a key regulatory step toward first‑in‑human testing of its
12 November 2025
 ·  ·  ·  ·  · 
Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

What happened today Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) announced that it has successfully achieved target loading concentrations for two topical rapamycin delivery technologies—4% in its lotion and 5% in a dermal patch. The company said it will start manufacturing clinical
11 November 2025
 ·  ·  ·  ·  · 
enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene Holdings Inc. (NASDAQ: ENGN) reported fresh preliminary data this morning from the pivotal cohort of its Phase 2 LEGEND trial of detalimogene voraplasmid (formerly EG‑70) in high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC) with CIS. The readout shows a
11 November 2025
 ·  ·  ·  ·  · 
Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences (NASDAQ: COGT) announced positive top‑line results from its Phase 3 PEAK trial testing bezuclastinib plus sunitinib in second‑line gastrointestinal stromal tumor (GIST), sending the stock sharply higher in Monday trading. The combination delivered a median progression‑free survival (mPFS)
10 November 2025
 ·  ·  ·  ·  · 
Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

What happened today Intellia Therapeutics (NASDAQ: NTLA) is under intense pressure after the company said the patient who experienced Grade 4 liver enzyme and bilirubin elevations in its Phase 3 MAGNITUDE study later died. In a Nov. 6 business update,
7 November 2025
 ·  ·  ·  ·  · 
Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported third‑quarter 2025 results this morning (Nov. 6), highlighting sequential revenue growth, materially higher gross margins, and steady commercial momentum for its tumor‑infiltrating lymphocyte (TIL) therapy Amtagvi. Management also reaffirmed full‑year revenue guidance and flagged
6 November 2025
 ·  ·  ·  ·  · 
1 … 5 6 7 8 9 … 15
Go toTop